ReviewVaccines2025
Antiviral Inactivated Vaccines: Looking to the Past to Face the Future-A Narrative Review.
Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Seroconversion Rates Following COVID-19 Vaccination in People Living with HIV: A Systematic Review and Meta-Analysis.Vaccines · 2026Review
- Article
- Nanotechnology-Enhanced Vaccines for Respiratory Infections: Opportunities and Challenges.International journal of nanomedicine · 2026Review
- Nano-adjuvants enhance the immunogenicity and safety of infectious bursal disease virus vaccines: a comprehensive review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Throughout human history, contagious infectious diseases have significantly impacted societies, shaping the fate of great dynasties and challenging economic and political systems, social relations, and the overall well-being of the human species. The SARS-CoV-2 pandemic brought unprecedented challenges, emerging in the context of extreme globalization and rapid technological development. The speed of viral spread, the highest absolute mortality rate caused by a viral agent in the last 100 years, and the severe economic and social consequences imposed an urgent need for vaccine development on a previously unimaginable timescale. The proven safety and efficacy of inactivated vaccines enabled the development and large-scale application of the first immunizer against SARS-CoV-2 in less than a year after the World Health Organization (WHO) declared the pandemic. In this review, we discuss the importance of inactivated antiviral vaccines and their historical impact in containing highly harmful diseases affecting humanity. We also explore the cellular mechanisms by which inactivated vaccines may induce immunogenic responses against viral pathogens. In addition, we bring to light a discussion about a fast, cost-effective, potentially efficient technology for large-scale immunizer production: High hydrostatic pressure (HHP), a method long supported by decades of preclinical studies and which is especially effective in the context of enveloped viruses. Finally, we discuss the role of inactivated antiviral vaccines in the face of advances in biotechnology and, therefore, the emergence of vaccines that use genetic engineering in their production, such as RNA, DNA and viral vaccines, which have gained special prominence during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.